Our Story
Everybody deserves a good night's sleep
Treating snoring since 1996
Good night. Good morning.
Everybody deserves a good night's sleep
Treating snoring since 1996
Good night. Good morning.
Everybody deserves a good night's sleep
Treating snoring since 1996
Good night. Good morning.

SleepDoctor is the Australian flagship brand of Passion For Life Healthcare.

Passion for Life Health Care, a renowned UK brand, has spearheaded the development of a range of innovative products aimed at addressing snoring and sleep apnoea. In 1998, we introduced the Throat Spray, marking the inception of our journey. Over the past two decades, we emerged as the leading snoring relief brand across Europe.

Our commitment to excellence is evident in our team of skilled scientists and technicians, who continuously strive to innovate and improve our offerings. Through collaborative efforts with pharmacists, dentists, ENT specialists, and other healthcare professionals, we ensure that our products are meticulously crafted to meet the diverse needs of our customers.

Sleep Doctor Snoring Relief, operates as the Australian counterpart of Passion for Life Health Care, continuing the tradition of excellence. With a comprehensive range of products tailored to different types of snorers, we stand as the sole brand in the snoring relief market dedicated to providing unparalleled support and solutions.
CLINICAL EVIDENCE

Mandibular advancement works in two distinct ways: to reduce air turbulence caused by airway obstruction, and to inhibit collapse of the upper airway. By moving the jaw progressively forward, mandibular advancement pulls the tongue and other connected tissues forward. This creates more space between the base of the tongue and the epiglottis. Advancement of the jaw acts on the muscles of the velopharynx and the cross-sectional shape of the upper airway. In a majority of patients, it will increase the calibre (or tone) of the velopharynx musculature, making it less prone to collapse. Various studies have shown that mandibular advancement:

  • Tightens the soft tissues of the pharynx’s lateral walls. This reduces air turbulence and the soft tissue vibration that causes snoring.
  • Activates the genioglossus muscle and increases airway muscle tone.
  • Changes pharyngeal pressures to normalize the physiological properties of the upper airway.
Clinical evidence that oral devices reduce snoring

Hoffstein concluded: Oral devices are beneficial in reducing snoring in the majority of patients. All of the randomized, placebo-appliance-controlled studies except one found significant reduction in snoring, independently of whether it was assessed objectively or subjectively. The Hoffstein review identified 89 publications dealing with oral device therapy involving a total of 3,027 patients between 1982 and 2006. It was found that the success rate, defined as the ability of oral devices to reduce apnoea/hypopnoea index to less than 10, was 54%. Snoring was reduced by 45%.

Ahrens et al: The Ahrens review identified 116 studies dealing with oral device therapy between 1982 and 2009. In concluded that, all types of oral devices investigated were effective in terms of improving AHI or RDI supporting the findings of Hoekema et al. (2004) that adjustable oral devices are generally effective irrespective of their various design features. Non-adjustable devices have poor evidence of effectiveness.

Serra-Torres: The Serra-Torres review focused solely on high level studies and meta-analyses and identified 22 between 2006 and 2016. It concluded that using oral devices helps to prevent snoring and excessive daytime sleepiness, reduce AHI significantly, and bring about beneficial changes in the upper airway. Adjustable and custom-made mandibular advancement devices give better results than fixed and prefabricated appliances. Monobloc devices give rise to more adverse events, although these are generally mild and transient.